[The 2026 Commercial Health Insurance Innovative Drug Catalog was released, and 12 drugs from 11 companies were successfully included] On November 14, reporters learned from the 2026 High-Quality Development Conference on Innovative Drugs held today that the 2026 Commercial Health Insurance Innovative Drug Catalog was officially released, and a total of 12 drugs from 11 companies were included in the catalog, covering tumors, rare diseases, gene therapy, CAR-T cell therapy and other fields. This is the second time that China has released a catalog of commercially available innovative drugs. Huang Xinyu, director of the Pharmaceutical Service Management Department of the National Medical Insurance Administration, said that the catalog of commercially insured innovative drugs is an institutional innovation in the construction of China's multi-level medical security system. It is an important starting point to further clarify the boundaries of basic medical insurance and promote the complementary development of basic medical insurance and commercial health insurance. As of the end of October 2026, the drugs in the first edition of the catalog have been deployed in 1,710 medical institutions and designated retail pharmacies, with a total of nearly 30,000 users, driving drug sales of about 600 million yuan, and the number of dispensing institutions has increased by about 140%. Xiaocai's note: The included drugs include three domestic CAR-T products: Hengrun Dasheng's Rannici Orenza Injection, Chongqing Precision Biotech's Pulge Oronza Injection, and Keji Pharmaceutical's Serigen Oronza Injection, Shanghai Xinzhi Pharmaceutical's Popidacoli Injection, and AstraZeneca Innovative drugs such as Eplrontex Sodium Injection, Novartis' Lutetium [177Lu] Tepavipitide Injection, Bogen's Tolfsin Injection, Sanofi's Calacizumab Injection, and Weijian (China) Pharmaceutical's Moglitizumab Injection and Broxolumab Injection. (Reporters Lu Afeng and Yu Miao)